Theranostec Inc

2:30 PM - 2:45 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Theranostec develops precision nanomedicines that significantly improve both the delivery and effectiveness of cancer therapies.

Currently, we are at pre-clinical stage with promising anti-cancer effect in vivo animal models. Our near-term plan is to file the IND application to the FDA and initiate clinical trials. Our long-term goal is to seek FDA approval.

We have received several non-dilutive federal funds, including multiple SBIR Phase I and Phase II grants for optimization and IND-enabling studies that will move our two drug candidates into Phase 1 clinical trials.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Precision Nanomedicine to Treat Tumors effectively: We at Theranostec developed a nano- autophagy inhibitor by integrating the power of nanotechnology and medicinal chemistry. Our drug can effectively eradicate cancer cells, particularly cancer stem cells while sparing normal cells. Our nano drug is effective as a single agent or in combination therapy. Our research shows tremendous success metrics in maintenance therapy to inhibit tumor recurrence. We attack the problem at its root, overcoming resistance and preventing cancer recurrence. Additionally, we developed a phototherapeutic nano-transformer that shows a curative effect in cancer models. Both programs strengthen the Theranostec pipeline that drive growth potential to capture multiple cancer indications in a $27B market. Theranostec received multiple SBIR grants for optimization and IND-enabling studies that will move both of our programs into Phase 1 clinical trials. Patents The chemical composition of our new drugs, the nanoparticle technology and applications are under strong patent protection. Publications Ma et al, Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy. Nature Communications, 2020, 11, Article number: 4615 Ma et al, A pH‐Driven Small‐Molecule Nanotransformer Hijacks Lysosomes and Overcomes Autophagy‐Induced Resistance in Cancer. Angewandte Chemie International Edition, 2022, Volume61, Issue35, e202204567
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Theranostec Inc